类风湿关节炎中的生物制剂难治性疾病:来自英国风湿病学会类风湿关节炎生物制剂登记的研究结果
该研究纳入2001至2014年间在英国风湿病学会类风湿关节炎生物制剂登记中启动一线肿瘤坏死因子抑制剂的类风湿关节炎患者,将启动第三类生物制剂定义为生物制剂难治。13502例中867例(6%)为难治,中位至第三类生物制剂时间为8年;多变量分析显示近期登记、女性、较年轻、病程较短、患者总体评估较高、健康评估问卷评分较高、目前吸烟、肥胖和更大社会剥夺与难治相关。
要点
- 13502例中867例(6%)为生物制剂难治,中位至第三类生物制剂时间为8年。
- 与难治相关的基线因素包括近期登记、女性、较年轻、病程较短、患者总体评估较高、健康评估问卷评分较高、目前吸烟、肥胖和更大社会剥夺。
- 作者认为生物制剂难治的病因发病机制需进一步研究,将护理支持等资源集中于这些患者可能有助于其获得更稳定、受控的疾病。
核心结论
- 这项首个全国性研究确定,在曾接受过生物制剂的患者中,生物制剂难治性疾病的比例至少为6%。
- 随着生物制剂选择增多,患者更换生物制剂的速度加快。
- 生物制剂难治性疾病的病因发病机制需进一步研究。
- 作者认为,将护理支持等资源集中于这些患者可能有助于其获得更稳定、受控的疾病。
研究设计与样本
- 研究纳入2001至2014年间在英国风湿病学会类风湿关节炎生物制剂登记中启动一线肿瘤坏死因子抑制剂的类风湿关节炎患者。
- 生物制剂难治定义为启动第三类生物制剂之日;随访截至2016年11月30日或死亡,以先发生者为准。
- 研究调查了生物制剂的更换模式和停药原因,采用Cox回归识别与难治性疾病相关的基线临床因素,并对缺失基线数据采用多重插补。
主要发现
- 13502例患者中867例(6%)为生物制剂难治,中位至第三类生物制剂时间为8年。
- 多变量分析中,与生物制剂难治性疾病相关的基线因素包括:近期登记的患者、女性、较年轻、病程较短、患者总体评估较高、健康评估问卷评分较高、目前吸烟、肥胖和更大社会剥夺。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. This analysis aims to quantify the frequency of, and identify factors associated with, bDMARD refractory disease. METHODS: Patients with RA starting first-line tumour necrosis factor inhibitor in the British Society for Rheumatology Biologics Register for RA from 2001 to 2014 were included. We defined patients as bDMARD refractory on the date they started their third class of bDMARD. Follow-up was censored at last follow-up date, 30 November 2016, or death, whichever came first. Switching patterns and stop reasons of bDMARDs were investigated. Cox regression identified baseline clinical factors associated with refractory disease. Multiple imputation of missing baseline data was used. RESULTS: 867 of 13 502 (6%) patients were bDMARD refractory; median time to third bDMARD class of 8 years. In the multivariable analysis, baseline factors associated with bDMARD refractory disease included patients registered more recently, women, younger age, shorter disease duration, higher patient global assessment, higher Health Assessment Questionnaire score, current smokers, obesity and greater social deprivation. CONCLUSIONS: This first national study has identified the frequency of bDMARD refractory disease to be at least 6% of patients who have ever received bDMARDs. As the choice of bDMARDs increases, patients are cycling through bDMARDs quicker. The aetiopathogenesis of bDMARD refractory disease requires further investigation. Focusing resources, such as nursing support, on these patients may help them achieve more stable, controlled disease.
引用
- Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018. PMID: 29980575. doi:10.1136/annrheumdis-2018-213378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。